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a  b  s  t  r  a  c  t
Digital  PCR  offers  very  high  sensitivity  compared  to  many  other  technologies  for processing  molecular
detection  assays.  Herein,  a process  is  outlined  for  determining  the  lower  limit  of detection  (LoD)  of two
droplet-based  digital  PCR assays  for point  mutations  of  the  epidermal  growth  factor  receptor  (EGFR)  gene.
Hydrolysis  probe  mutation-detection  assays  for EGFR  p.L858R  and p.T790M  mutations  were  characterized
in  detail.  Furthermore,  sixteen  additional  cancer-related  mutation  assays  were  explored  by  the  same
approach.  For  the EGFR  L8585R  assay,  the  assay  sensitivity  is  extremely  good,  and  thus,  the  LoD  is  limited
by  the  amount  of  ampliﬁable  DNA  that  is  analyzed.  With 95%  conﬁdence  limits,  the  LoD  is  one  mutant  in
180,000  wild-type  molecules  for the  evaluation  of 3.3 g of  genomic  DNA,  and  detection  of one  mutantimit  of detection
ssay  sensitivity
GFR  L858R
GFR T790M
molecule  in  over  4 million  wild-type  molecules  was  achieved  when  70 million  copies  of DNA  were
processed.  The  measured  false-positive  rate for the  EGFR  L8585R  assay  is  one  in  14  million,  which  indicates
the  theoretical  LoD  if an unlimited  amount  of DNA  is evaluated.  For  the EFGR  T790M  assay,  the  LoD  is  one
mutant  in  13,000  for analysis  of  a 3.3 g  sample  of genomic  DNA, and  the  dPCR  assay  limit  sensitivity
approaches  one  mutant  in  22,000  wild-type  molecules.
©. Introduction
.1. Digital PCR
Invention of the Polymerase Chain Reaction (PCR) [1] changed
ife science research and molecular diagnostics. Now, digital PCR
dPCR) is changing the ﬁeld of PCR and re-deﬁning expectations for
utation detection. The power of digital PCR arises from evaluating
ndividual molecules as positive or negative for a particular param-
ter, such as mutation status. For many assays, dPCR sensitivity is
igniﬁcantly higher than traditional PCR analysis, and the accuracy
nd precision of the assay improves by counting larger numbers of
olecules individually. The sensitivity of digital PCR will facilitate
Abbreviations: PCR, Polymerase Chain Reaction; EGFR, epidermal growth factor
eceptor; LoB, limit of blank; LoD, limit of detection; N, total number of droplet
vents  counted; NWT , number of droplets with only wild-type DNA; NMut , number of
roplets with only mutated DNA; , average number of targets “loaded” per droplet;
, fraction of PCR-positive droplets; R, ratio of mutant to wild-type molecules; FP ,
verage number of false-positive events; RFP , average false positive rate (FP/#WT).
∗ Corresponding author. Tel.: +1 978 495 3300.
E-mail  address: milburyc@raindancetech.com (C.A. Milbury).
1 These two authors contributed equally to the manuscript.
ttp://dx.doi.org/10.1016/j.bdq.2014.08.001
214-7535/© 2014 Published by Elsevier GmbH. Open access under CC BY-NC-ND license 2014  Published  by  Elsevier  GmbH.
detection limits that redeﬁne our understanding of disease onset,
progression, and recurrence.
One  particularly attractive application of digital PCR is the quan-
titative detection of a small number of mutated DNA molecules
among a large number of wild-type molecules, which is rele-
vant to cancer research, and especially for the detection of minor
alleles. Cancerous tissue is often highly heterogeneous and cancer
biomarkers vary across types of disease and stages of disease pro-
gression which complicates cancer detection and identiﬁcation at
early stages. Subclonal populations of cells within a tumor may
contain a mutation that differs from the primary mutation, but
the subclonal mutation could be correlated to a prognosis and/or a
response to speciﬁc therapy regimens. Similarly, detecting muta-
tions in circulating tumor DNA (i.e., a Fluid BiopsyTM sample) is a
relatively simple and non-invasive approach to monitoring disease
recurrence, which requires a high sensitivity of mutation detection
to provide effective therapies at the earliest stage of progression
[2–4]. These examples reﬂect the need for mutation detection tools
that are qualitatively more sensitive than existing tools, enabling
sensitivity better than 1 in 10,000 and maximized to enable trans-
Open access under CC BY-NC-ND license.formational advances in cancer research.
Digital PCR technologies can be deeply sensitive and highly
precise for detection of low abundance minority alleles, such as
those observed in progressive cancer and metastatic samples. The
.
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Table  1
EGFR  assay details.
Protein Variant p.T790M p.L858R
Nucleotide Variant c.2369C>T c.2573T>G
Amplicon  Location chr7: 55249045-55249095 chr7:55259486-55259563
Amplicon  Length 51 base pairs 78 base pairs
Forward  Primer 5′-CCTCACCTCCACCGTGCA-3′ 5′-GCAGCATGTCAAGATCACAGATT-3′
Reverse Primer 5′-AGGCAGCCGAAGGGCA-3′ 5′-CCTCCTTCTGCATGGTATTCTTTCT-3′
TC/3IABkFQ/ /VIC/-AGTTTGGCCAGCCCAA-MGBNFQ
C+TC/3IABkFQ/ /6FAM/-AGTTTGGCCCGCCCAA-MGBNFQ
 DNA Technologies) TaqMan® MGB  (Life Technologies)
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Table 2
Samples evaluated to measure and verify the sensitivity of each EGFR assay.
Sample (Mut/WT) EGFR  T790M EGFR L858R
0% (wild-type only) N = 58 N = 71
∼0.5 to 1.0% N = 4 N = 4
∼0.05 to 0.1% N = 4 N = 4
T
DWild-type Probe /5TET/T+CATC+A+C+GC/ZEN/A+GC
Mutant  Probe /6FAM/T+CATC+A+T+GC/ZEN/A+G
Probe  Type (Vendor) PrimeTime® LNA-ZEN (Integrated
pidermal growth factor receptor (EGFR) is frequently impacted by
utations that arise in cancer. Mutations in the EGFR gene (chromo-
omal locus 7p12.3-p12.1) are common across several cancer types,
nd the mutations often result in altered expression and activity.
pregulation and overexpression of EGFR can lead to uncontrolled
ellular division, resulting in rampant tissue growth and lead to
ancer. A common example is a point mutation (c.2573T>G) in
xon 21 of EGFR, commonly known as variant L858R. This type of
ctivating mutation occurs frequently in epithelial cancers, partic-
larly lung cancer and glioblastomas. Non-small cell lung cancers
NSCLC) are some of the most common cancers in the world and
re frequently associated with mutations in EGFR. Two  tyrosine
inase inhibitors (TKIs), Geﬁtinib (Iressa®) and Erlotinib (Tarceva®),
re common treatments for NSCLC. Nearly all responders to treat-
ent possess somatic alterations in exons 18–21 of the EGFR gene.
pproximately 90% of EGFR mutations in NSCLC are highly vari-
ble deletions located in exon 19 or point mutations in exon 21[5].
he L858R and T790M alterations are two of the most frequent
GFR mutations. The EGFR T790M mutation is particularly impor-
ant because it is linked to known drug resistance, reinforcing the
alue of early detection [6].
Herein, the process of determining lower limits of detection
LoD) for assays performed using the RainDance RainDrop® digi-
al PCR system for the detection of mutations in EGFR and other
ommon cancer-related mutations is reported. The data demon-
trate that digital PCR supports the potential for detecting mutated
NA in highly heterogeneous tumor samples or body ﬂuids, which
rovides a broad view of all biomarkers arising from heterogeneous
nd highly localized tumor(s).
. Methods
.1. EGFR assays for digital PCR analysis
Assays comprised of primers and hydrolysis probes were devel-
ped to screen for EGFR T790M and L858R point mutations via
igital PCR. The digital PCR system utilized for this evaluation
as the RainDrop® Digital PCR System (RainDance Technologies).
able 1 presents the assay details for the EGFR T790M and L858R
ssays. Probes were labeled with 6-carboxyﬂuorescein (FAM, ex
94 nm/em 522 nm), VIC (from ABI, ex 528 nm/em 554 nm), or TET
from Integrated DNA Technologies, ex 522 nm/em 539 nm). The
GFR L858R TaqMan® MGB  probes were designed using the Life
able 3
igital PCR reagent components.
Reagent Vendor 
TaqMan® Genotyping Master Mix  Life Technolog
TaqMan®  MGB  Probes Life Technolog
PrimeTime® LNA-ZEN qPCR Probes Integrated DNA
Oligonucleotide primers Integrated DNA
Droplet Stabilizer RainDance Tec
WT  genomic DNA control Promega 
Mutant plasmid DNA control (GeneArt® Gene Synthesis) Life Technolog
DNase/RNase-free water Sigma–Aldrich∼0.005 to 0.01% N = 4 N = 4
∼0.0005 to 0.001% N = 4 N = 4
Technologies online TaqMan design tool, whereas the PrimeTime®
LNA-ZEN probes were designed with the assistance of Integrated
DNA Technologies, as these are custom probes (non-cataloged
item). The EGFR T790M probe sequence contains LNA nucleotides
that are denoted with “+”.
2.2. Samples and reagent components
A series of experimental samples were processed to determine
the LoD for each EGFR assay. Table 2 summarizes the replicate
samples that were analyzed in this study. A two-part design was
executed; one subset of samples is composed of wild-type genomic
DNA samples to assess the false positive rate of the assay, and the
second subset included a mutation titration series to verify the
linearity and sensitivity of the assay.
The EGFR T790M and L858R mutation templates were synthetic
GeneArt® plasmid templates (Life Technologies Inc.). Each plas-
mid was  linearized using restriction enzyme digestion. Wild-type
genomic DNA (G3041, Promega Inc.) was nebulized to approx-
imately 3 kb in length according to manufacturer’s protocols
(K7025-05, Life Technologies). DNA was quantiﬁed and qualiﬁed
using a NanoDrop 2000 spectrophotometer. Fragmentation length
was conﬁrmed via gel electrophoresis.
Following DNA preparation, PCR reagent components were pre-
pared as presented in Table 3 in a pre-PCR room to limit the risk
of reagent contamination. All sample PCR reactions were prepared
to 50 l volumes, containing approximately ∼20,000 copies/l of
genomic DNA (∼3.3 g DNA per each 50 l reaction). The mutant
template was  only incorporated into the second subset of samples,
following a titration of the DNA sample, according to Table 2.
Outside  of the samples deﬁned within this evaluation, prelim-
inary assessment, veriﬁcation, and optimization of both assays
was performed. The false positive mutant count is zero for both
Item # Final concentration
ies 4371355 1×
ies Custom 0.2 M
 Technologies Custom 0.2 M
 Technologies Custom 0.9 M
hnologies 20-00803 1×
G3041 ∼20,000 copies/l
ies Custom Variable by sample type
 W4502-1L To volume
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Table  4
Thermal cycling protocols.
A. EGFR T790M B. EGFR L858R
Step Temp Time Cycles Step Temp Time Cycles
Polymerase activation 95 ◦C 10 min  1 Polymerase activation 95 ◦C 10 min  1
Denaturation  95 ◦C 15 s Denaturation 95 ◦C 15 s
}
Annealing 58 ◦Ca 15 s
}
50 Annealing & Extension
60 ◦Ca 60 s
45
Extension  60 ◦C 45 s
◦ ◦
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sIncubation 98 C 10 min  1 
Final  hold 12 ◦C Indeﬁnite 
a A slow ramping speed (0.5 ◦C) was used during cooling from the denaturation s
ssays, though some false-positive wild-type counts have been
bserved for the EGFR T790M assay, possibly due to non-speciﬁc
robe hydrolysis.
.3.  Emulsion generation, thermal cycling, and sample reading
Samples  were loaded onto the RainDrop® Source instrument
RainDance Technologies), following operating guidelines, to emul-
ify the sample. The RainDrop® Source instrument uses real-time
losed-loop image control to ensure uniformity of droplet creation
oth within and across runs. Each 50 l sample was emulsiﬁed into
 picoliter droplet volumes, partitioning single molecule of DNA
nto approximately 10 million droplets.
Following emulsion generation on the RainDrop® Source
nstrument, the samples were thermal cycled following the pro-
ocol outlined in Table 4. A Bioer GenePro thermal cycler was
sed. Thermal cycled samples were loaded onto the RainDrop®
ense instrument (RainDance Technologies). The RainDrop® Sense
nstrument uses a 488 nm laser to read the FAM and VIC/TET ﬂuo-
escence intensity per droplet.
.4. Assessment of additional cancer assays
The approach to determine assay sensitivity was employed to
ssess sixteen cancer-related assays in addition to EGFR. The assay
esigns are listed in Appendix Table A1. Analysis of wild-type DNA,
s well as a mutation-titration series, was evaluated for each of
hese assays. Assay designs included TaqMan® MGB probes as well
s custom PrimeTime® LNA-ZEN qPCR probes (similar to those used
or the two EGFR assays). Reagent composition and sample lay-
ut followed the methods presented above, and limits of detection
ere determined by the process outlined in the following sections.
ig. 1. EGFR T790M. The two  dPCR plots are from a sample containing wild-type and muta
NA loading. A small number of false-positive samples are routinely observed with this as
ample-to-sample variability.Incubation 98 C 10 min  1
Final hold 12 ◦C Indeﬁnite
 the annealing step.
2.5.  Data analysis with the RainDrop Analyst data analysis
software
After evaluating all samples using the RainDrop® digital PCR
System, data from cluster plots were spectrally-compensated and
analyzed using the RainDrop Analyst data analysis software, follow-
ing standard procedures. The sample containing the highest mutant
titration was used as a control sample to deﬁne gates around the
cluster of droplet events displaying signal from only wild-type
copies (identiﬁed by VIC/TET ﬂuorescence) and the mutant clus-
ter (identiﬁed by FAM signal). These gates were applied across all
samples evaluated within each assay. The same mutant gate was
set within all wild-type only samples that were evaluated. For all
wild-type only samples, any droplets with mutant signal (droplet
events that are counted within the mutant gate) are considered
mutant-positive, and are therefore false-positive events.
Examples of gated dPCR cluster plots for the EGFR T790M and
L858R assays are presented in Figs. 1 and 2, respectively. For
the EGFR T790M data in this report, the red target gates (Fig. 1)
were relatively conservative (e.g., larger), whereas the gates for
the EGFR L858R data relatively stringent (e.g., narrowly deﬁned
regions; shown in red, Fig. 2). Fig. 3 demonstrates the difference
between smaller elliptical gates (stringent) and larger rectangu-
lar (more conservative) gates. Setting larger gates provides a more
inclusive count of droplet events, but also leads to a higher prob-
ability for counting false-positive events due to gates overlapping
with neighboring clusters or ambiguous single events being cap-
tured within the gated region. Though the gates for EGFR L858R are
more stringent gates, they still capture approximately 98% or more
of events associated with each cluster. The difference in droplet
count between the stringent and conservative gates is typically
quite small. Establishing a balance between stringent and conser-
vative gate setting is deﬁned by the user, based on tolerance for
nt DNA (left) and a wild-type only sample (right) with the maximum recommended
say. Rectangular gates were applied for EGFR T790M, as this assay can exhibit some
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eig. 2. EGFR L858R. The two dPCR plots are from a sample containing wild-type and
NA loading. 67 of 71 wild-type only samples analyzed with this assay yielded no
ates were applied for the EGFR L858R assay, as clusters are typically tight and exhi
alse-positives (leading to lower sensitivity) versus risk of missing
 small fraction of true-positive events.
. Statistical calculations.1.  Assessing sensitivity of dPCR assays
The sensitivity of a mutation detection assay is deﬁned by a
hreshold for making positive calls about mutational status on
ig. 3. Comparison of stringent (small elliptical) gates to conservative (rectangular) gate
lliptical gate is at least 98% of the population in rectangular gates. A smaller gate will mit DNA (left) and a wild-type only sample (right) with the maximum recommended
positives, and the other 4 samples each yielded 1 false-positive droplet. Stringent
nimal sample-to-sample variability.
individual  samples with a known level of conﬁdence. For quan-
titative real-time PCR (qPCR), the baseline for mutation detection
is generated by evaluating negative controls (i.e., samples that do
not contain target DNA). The quantiﬁcation cycle (Cq) is the cut-off
for qPCR that deﬁnes a concentration below which a mutation-
containing sample cannot be called with conﬁdence. Similarly, for
dPCR, the baseline level of false-positive molecule counts deter-
mines what concentration of true mutant-positives can be detected
with statistical conﬁdence. The following sections describe the
s for one of the EGFR L858R samples. The number of droplet events counted in the
ss a small percentage of true-positives but will minimize false-positives.
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mig. 4. Two-dimensional dPCR cluster plot landscape illustrating a heterogeneous
ample  analyzed with two  probes (i.e., a duplex assay).
nalysis and process for evaluating the limit of blank (LoB) and
imit of detection (LoD) for mutation detection with digital PCR. This
pproach is not limited to mutation detection, and should be appli-
able for other minor allele detection approaches (i.e., pathogen
nd viral detection).
.2.  Conversion of droplet event counts to molecule counts
When  a bulk solution of homogeneously-distributed target
olecules, with an average concentration of less than one molecule
er partition volume, is partitioned into droplets, some droplets
ill contain more than one target molecule. However, a droplet
artition that initially contains more than one identical target
mpliﬁed by PCR is not distinct from a droplet initially contain-
ng only one target molecule. Therefore, the actual number of target
olecules must be calculated from the measured number of target-
ontaining partitions (i.e., droplets).
The partitioning of molecular targets into droplets is described
y a Poisson distribution [7–9], where P(k;) is the probability for
here to be k targets in one droplet when the population of all
roplets contains an average “loading” of  targets per droplet. For
 system in which 50 molecules are loaded into 100 droplets,  is ½.
lternatively, if 500 molecules are loaded into 100 droplets, then 
s 5.
(k; ) = 
ke−
k!
(1)
The  fraction of PCR-negative drops (p−) is:
− = P(0; ) = e− (2)
nd  the fraction of PCR-positive drops (p), which is inclusive of all
roplets with one or more molecules of target DNA is:
 = 1 − p− = 1 − e− (3)
A  duplex assay enables detection of two independent molecular
argets, e.g., wild-type DNA (WT)  and mutant DNA (Mut). When a
ample containing both mutant and wild-type DNA is analyzed,
our clusters of dPCR data are evident, as depicted in the two-
imensional histogram of the ﬂuorescence intensities in Fig. 4.
The  partitioning of fragments of homoduplex DNA into droplets
s independent of mutational status,2 and the joint probability of
wo independent events is equal to the product of the individual
robabilities. Therefore, the fraction of wild-type-only droplets is:
WT = p(WT) · p(noMut) = (1 − e−w ) · e−m (4)
2 This section of the report is applicable when the sample DNA has been processed
o  retain the native homoduplex character. For cases in which the DNA has been
ragmented by heating or subject to temperature above the melting temperature,
he  double-stranded DNA will likely denature and re-anneal into heteroduplex frag-
ents, and the analysis approach would not be valid.n and Quantiﬁcation 1 (2014) 8–22
where m is the average “loading” of mutant targets per droplet,
and w is the average “loading” of wild-type targets per droplet.
The number of wild-type only droplets is:
NWT = N · (1 − e−w ) · e−m (5)
Similarly,  the numbers of droplet events corresponding to other
combinations of mutant and wild-type DNA are:
NMut = N · e−w · (1 − e−m ) (6)
NNeg = N · e−w · e−m (7)
NDual = N · (1 − e−w ) · (1 − e−m ) (8)
This  series of four equations (Eqs. (5)–(8)) contains only two
unknown quantities (w and m) and these values can be calculated
by measurement of at least three quantities from the set of (N, NWT,
NMut, NNeg, and NDual). In most cases, it is recommended that N, NWT,
and NMut are used to calculate w and m following Eqs. (9) and (10).
Alternative methods for selecting and processing information from
gated clusters of droplet events are discussed in the Appendix.
w = − ln
⎛
⎝1 + NMut−NWTN +
√(
1 + NMut−NWTN
)2 − 4·NMutN
2
⎞
⎠ (9)
m = − ln
⎛
⎝1 + NWT −NMutN +
√(
1 + NWT −NMutN
)2 − 4·NWTN
2
⎞
⎠ (10)
Finally, the ratio of mutant to wild-type molecules in the sample
is given by:
R = m
w
(11)
Appendix Tables A3–A6 contain the droplet event counts and
calculated wild-type and mutant DNA molecule counts for the EGFR
T790M and L858R samples evaluated.
3.3. Estimation of 95% conﬁdence intervals
Conﬁdence intervals (CI) deﬁne a range of values which is likely
to include the true value of the sample. Conﬁdence intervals are
constructed at a conﬁdence level (e.g., 95%), which deﬁnes the like-
lihood that the true value is within the range.
When a DNA sample is partitioned, the probability of a droplet
being either PCR-positive or PCR-negative follows a binomial dis-
tribution [8,10]. When the number of PCR-positive droplets (Np) is
fairly large (>20), the binomial distribution is approximated with a
normal distribution with a mean of Np and a variance of Np(1 − p)
[10,11] so the 95% conﬁdence interval for Np is approximated by
{Np ± 1.96
√
Np(1 − p)}.  In the case of rare mutation detection, p
is small enough that the conﬁdence interval for Np simpliﬁes to
{Np ± 1.96
√
Np}.
The normal approximation is not appropriate for very small
values of Np (<20). For such a case, a Poisson distribution
with Np as the expected value is a better approximation [12].
Table 5 presents Excel function (Microsoft) formulas for Np < 20
and Np > 20, such that one can calculate the conﬁdence lim-
its in an Excel spreadsheet. Alternatively, web-based calculators
that use binomial distributions are available. Online tools include
uCountSM from The Wittwer Lab at the University of Utah
(https://dna.utah.edu/ucount/uc.php) [13] or the Exact Binomial
and Poisson Conﬁdence Intervals calculator by John C. Pezzullo
(http://statpages.org/conﬁnt.html) [14].
With the RainDrop® dPCR System, 25–50 l samples are par-
titioned into 5-picoliter droplets, which yields 5–10 million
individual droplets. The recommended maximum loading of total
C.A. Milbury et al. / Biomolecular Detection and Quantiﬁcation 1 (2014) 8–22 13
Table  5
Conﬁdence intervals for various mutant-positive droplet event counts (Np). Np is the count of mutant-positive droplets, which includes droplets that contain only mutant
molecules and droplets that contain both mutant and wild-type molecules.
Conﬁdence limits Np = 0 and up Np > 20
99% CI lower limit CHIINV(0.995, 2Np)/2 Np − NORMSINV(0.995)*sqrt(Np)
99% CI upper limit CHIINV(0.005, 2Np + 2)/2 Np + NORMSINV(0.995)*sqrt(Np)
95%  CI lower limit CHIINV(0.975, 2Np)/2 Np − NORMSINV(0.975)*sqrt(Np)
h
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s95% CI upper limit CHIINV(0.025, 2Np + 2)/2 
90% CI lower limit CHIINV(0.95, 2Np)/2 
90%  CI upper limit CHIINV(0.05, 2Np + 2)/2 
uman genomic DNA is 10% (i.e., one genome equivalent per 10
roplets), and for most digital PCR applications, the amount of
utant DNA within the sample is normally present at a small
raction of the wild-type DNA. At this low fraction, very few
utant-positive droplets are expected to contain more than one
opy of the mutated DNA fragment, so the number of mutant-
ositive droplets is no different from the number of mutant molecules
m = pm). For example, in the mutant titration series, wild-type
NA was loaded into ∼10% of the drops, and the highest mutant
oading was present in only ∼0.06% of the drops, so m = 0.0006,
nd pm = 1 − e−m = 0.9997m, so the difference between the two  is
ithin 0.03%. Therefore, the quantity, Np, is used interchangeably
o refer to mutant positive droplets and mutant DNA molecules in
his paper.
For  mutation detection applications, the number of wild-type
argets is usually much greater than the number of mutant targets,
nd the uncertainty in the ratio of the two will be dominated by the
utant counting. The 95% CI of the ratio (R) of mutant to wild type
re given as below:
low =
pm low
w
(12)
high =
pm high
w
(13)
.4.  Assessing the frequency of false-positives
To determine application and assay sensitivity using any molec-
lar detection technology, one must account for signal-to-noise
imitations. Similarly, for mutation detection assays using digi-
al PCR, false-positives might arise from ﬂuorescence detection
“system”) noise and molecular biology (“assay”) noise. Comparing
amples to negative controls is typically necessary to classify muta-
ional status as positive or negative. The Clinical and Laboratory
tandards Institute (CLSI) guidelines recommend measurement of
t least 60 negative samples to assess the probability distribu-
ion function of false-positive events detected in negative control
amples.[15]
Fig. 5. False-positives measured in EGFR T790M (left, FP =Np + NORMSINV(0.975)*sqrt(Np)
Np − NORMSINV(0.95)*sqrt(Np)
Np + NORMSINV(0.95)*sqrt(Np)
In this work, collections of wild-type only samples were ana-
lyzed with the EGFR T790M and L858R assays. The data from EGFR
T790M in Fig. 5 reveals an average false-positive count (FP) of
39 mutant molecules per sample, which was measured from 58
negative control samples that each contained, on average, 862,147
wild-type molecules. For purposes of assessing the false-positive
distribution displayed in Fig. 5, the mutant count from each indi-
vidual wild-type sample was  normalized to the average number
of wild-type counts using the average false positive ratio (RFP,
the average false-positive ratio of all negative control samples) of
4.5E−5 to compensate for differences in the absolute number of
molecules analyzed in each sample.
In contrast to the EGFR T790M assay, the data from L858R yields
only 4 samples out of 71 with one false-positive event detected
(FP = 0.06) and a false positive ratio of 7.1E−8. Fig. 5 reveals that
the number of false-positive mutant counts follows a Poisson dis-
tribution in both cases, conﬁrming that the Poisson model is a valid
approximation of the measured data. (Note that applying the Pois-
son model ﬁt to the false-positive data is not related to the Poisson
loading correction described in previous sections.)
A dPCR practitioner often evaluates and reports the conﬁdence
level when assigning mutational status to a sample containing a
number of positive events that is very close to the false-positive
baseline. For this purpose, a hypothesis (signiﬁcance) test is exe-
cuted and a p-value is calculated. The p-value is the probability that
the observed mutant count or higher falls within the distribution of
false-positive counts measured from negative control samples. In
this case, the null hypothesis is: “there is no difference between the
sample and negative controls.” The null hypothesis is rejected when
the p-value is less than a speciﬁed signiﬁcance level. The choice of
signiﬁcance level at which to reject the null hypothesis depends
on the application and user preference. For clinical molecular anal-
ysis, common choices for p-value thresholds are 0.05 (95%) and
0.01 (99%); the analysis described in this report is based on a 95%
conﬁdence threshold.
Two  EGFR T790M mutant-positive samples are highlighted
below to demonstrate the calculation of p-values. P(k;FP) rep-
resents the Poisson distribution that estimates the frequency of
 39) and L858R (right, FP = 0.06) negative controls.
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Fig. 6. Relationship between the limit of blank (LoB) and the limit of detection
(LoD).  (a) The blue curve is the distribution of measurements from negative samples;
˛-error refers to false-positive mutation calls. (b) The red curve is the expected dis-
tribution of measurements from positive samples at the LoD concentration;  ˇ error
refers to false-negative mutation calls. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 6
Calculation of LoB and LoD from the average false-positive counts.
FP LoB LoD
0 0 3
0–0.05  1 5
>0.05  FP + 1.645
√
FP + 0.8 (1.645 +
√
1.6452 + 4LoB)
2
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alse-positives. Because these positive samples have very similar
ild-type load to the negative control samples, it is assumed that
he false positive ratio is consistent with negative samples. From
he ratio, FP is calculated for each sample, followed by calculating
he p-value.
Sample 1 (#1 in Appendix Table A5): measured mutants = 45,
FP = 39,
-value =
∞∑
k=45
P(k; FP) = 1 −
44∑
k=0
P(k; 39) = 0.17
Sample 2 (#5 in Appendix Table A5): measured mutant
vents = 81, FP = 40,
-value =
∞∑
k=81
P(k; FP) = 1 −
80∑
k=0
P(k; 40) = 8.7E − 9
In the ﬁrst sample, a measurement of 45 mutant molecules
esults in a p-value of 0.17, which is greater than 0.05 (i.e., 5%
igniﬁcance level for p-value), and therefore, the sample is not sig-
iﬁcantly different than the wild-type only controls. In contrast,
he second sample has a p-value of 8.7E−9, which indicates that
his sample is signiﬁcantly resolved from the negative controls.
ppendix Tables A5 and A6 list the p-values calculated for the rest
f the mutant-positive titration samples for the EGFR T790M and
858R assays. An Excel equation could be used to calculate the
-value as shown below:
-value = 1 − POISSON.DIS(NMut − 1, FP, TRUE) (14)
.5.  Estimating assay sensitivity and the limit of detection (LoD)
The  limit of detection (LoD) and limit of blank (LoB) are metrics
hat describe the sensitivity of an analytical procedure [15–18].
ig. 6 depicts how the LoB and LoD are deﬁned at stated error
ates. The  ˛ error rate indicates the fraction of all measurements of
rue negative samples that will be greater than the LoB (i.e., false-
ositive mutation call). The  ˇ error rate indicates the probability
f a false-negative mutation call (i.e., measurement less than LoB)
rom a sample with a true value equal to the LoD. For the analyses in
his paper,  ˛ error (false positive) and  ˇ error (false negative) rates
re 5%, which is a common approach. In practice, the selection of
 and  ˇ values is largely dictated by the application. For example,
here may  be applications in which both false positive and false
egative mutation calls are unacceptable, and one would decide
o lower the  ˛ and  ˇ rates (resulting in a more conservative LoD).
ome applications may  dictate a relatively high mutational abun-
ance threshold (i.e., well-separated from analytical performance)
o avoid unnecessary and expensive validation tests. Conversely,
he occurrence of false negatives is not acceptable in some appli-
ations. In such cases, the ˇ-error value would be conservative to
eﬂect the needs of the application.
In this report, false-positive droplet event probability (i.e., data
hown in Fig. 5 and represented as the blue curve in Fig. 6 panel
) was determined from a series of samples that each contained
pproximately the same level of wild-type DNA. The false-positive
ate is likely dependent (but not necessarily linearly proportional)
ith respect to wild-type load. Unless all samples are expected
o contain the same approximate level of DNA, evaluating false
ositives with varying wild-type loads is recommended for assays
f interest. Minimally, one should consider the desired LoD, and
ow much DNA should be evaluated to achieve that sensitivity.
or example, detection of 1 mutant in 1000 wild-type molecules
ill require a substantially smaller amount of total DNA than what
ould be required to attempt detection of 1 mutant in 1 million
ild-type molecules. The total amount of sample DNA does notNote: non-integers should be rounded up to the nearest integer.
guarantee a level of sensitivity, but sufﬁcient input DNA is neces-
sary to support the desired LoD.
In addition to characterizing the false-positive distribution by
processing wild-type only samples, CLSI guidelines [15] recom-
mend characterization of the distribution of measured droplet
events for positive samples with concentrations at the limit of
detection. However, in this report, it has been demonstrated that
the distribution of false-positive counts follows a distribution that
arises from counting uncertainty (i.e., a Poisson distribution) and it
has been assumed that the dominant variability in true positive
counting also arises from counting uncertainty. Therefore, “true
positive” distribution (i.e., the red curve in Fig. 6 panel B) is con-
sidered a Poisson function as well, for the purpose of determining
the LoD. Alternatively, one could estimate the LoB and LoD follow-
ing a non-parametric approach with a sufﬁcient number of negative
and low-level positive control samples to adequately represent the
probability distributions with empirical data [17].
Table 6 reports the LoB and LoD at various average false-positive
levels, FP, assuming a Poisson probability model ﬁt to empirical
data. In this analysis, ˛-error and ˇ-error are set at 5%. For FP
greater than 0.05, a normal approximation with a correction is used
C.A. Milbury et al. / Biomolecular Detection
Table  7
Droplet event and molecule counts from 58 EGFR T790M wild-type samples.
Average Standard deviation Total
Total droplets
processed (N)
9,049,729  683,030 524,884,260
Mutant only droplets 35.5 7.1 2059
Mutant molecules
(false-positives)
39  7.8 2265
Wild-type only 822,325  68,465 47,694,859
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Wild-type molecules 862,147 72,261 50,004,523
o describe the Poisson distribution to simplify the calculation of
oB and LoD with an analytical expression.
. Results and discussion
.1.  EGFR T790M
.1.1.  EGFR T790M limit of detection
Appendix Table A3 contains the raw data from 58 wild-type only
amples that were processed to calculate the LoB and LoD for the
GFR T790M assay; Table 7 contains the summarized data from
egative control samples. Based on the wild-type only controls,
nd the equations described in Table 6, the LoB for EGFR T790M
utations in a single sample with an average measured count of
62,147 copies of genomic DNA is 1 mutant in 17,000 wild-type
olecules, and the LoD is 1 in 13,000. This represents the high-
st sensitivity that can be achieved with a single sample processed
ith one assay reaction. One might split a single sample across
ultiple dPCR reactions if an extremely sensitive LoD is desired
nd the DNA is plentiful. For cases with enough sample DNA to
plit across 8 samples at maximum loading (i.e., 26 g of human
enomic DNA processed in an 8-channel microﬂuidic chip), then
he analysis described above results in a demonstrated LoD of 1
n 18,000. Furthermore, if data from all 58 wild-type samples are
ooled together (representing a single replicate of 200 g of DNA
egative control DNA), then the LoD is 1 in 20,000. Finally, we
xtrapolate to determine that the LoD would continue to improve
s a function of the wild-type load, and reach a plateau at the mea-
ured false-positive rate of 0.0045% (or 1 in 22,000). Fig. 7 displays
ig. 7. LoD performance model for EGFR T790M. Blue points represent the empirical
ata collected from 58 negative samples pooled to different levels. The red curve is an
xtrapolation of the data to represent evaluation of more DNA. The green dashed line
s the LoD if the amount of DNA available for analysis is unlimited. (For interpretation
f  the references to color in this ﬁgure legend, the reader is referred to the web
ersion  of this article.) and Quantiﬁcation 1 (2014) 8–22 15
the LoD assessed from collections of empirical data (blue points) as
well as the extrapolated sensitivity that approaches a limit equal
to the measured false-positive rate. We  do not envision practical
applications for human genomic DNA analysis that would yield
sufﬁcient DNA and justify splitting a sample over many chips or
channels. However, the demonstration and extrapolation highlight
the transformational sensitivity that the assay and technology can
deliver as well as emphasizing that the practical sensitivity is likely
to be limited by the amount of available sample DNA. Further-
more, applications probing non-human genomes (e.g., viral load or
pathogen detection and microbial genomics) are more likely to take
advantage of ultra-high sensitivity workﬂows due to the possibility
for large quantities of input DNA with relatively small genomes.
The  data from the wild-type samples that is reported in Fig. 5
presents a clearly-deﬁned probability function related to the false-
positives. No-template control samples do not yield false-positives,
and multiple lots of wild-type control DNA (i.e., negative controls)
yield the same level of false-positives. This evidence suggests that
the false-positive droplet events are not due to contamination of
the reagents or wild-type samples, and the false-positive back-
ground is expected to be present in all samples with this assay. For
the purposes of demonstrating this analysis approach, the average
background level of false-positive mutant molecules can be consid-
ered as a systematic offset, and the offset can be subtracted from
the number of mutant molecules detected in any unknown sam-
ples. The result is a more accurate measurement of the true level of
mutant molecules present in the sample, albeit with no improve-
ment to the precision of the measurement. The limit of detection,
which is deﬁned as the true mutant concentration within a sam-
ple that will be detected within stated  ˛ and  ˇ error limits, can be
recalculated after removal of the systematic false-positive offset;
see Appendix Table A7 for the associated calculations. The LoD for
the EGFR T790M assay, after correction for the false-positive back-
ground, is 1 in 34,000 when one 50ul sample at ∼10% wild-type
loading is processed.
The  key to this analysis approach is establishing conﬁdence
that the false-positive background is universal for all samples. For
the EGFR T790M assay, this approach is justiﬁed by processing
commercially-available blended human cell-line DNA and no-
template controls. Additional testing, outside the scope of this
document, has evaluated several individual DNA samples (Coriell
Specimen Collections), as well as synthetic plasmid templates,
wherein comparable numbers of false-positive events have been
observed. The approach would be solidiﬁed by sound explanation
of the reason (other than contamination) for the level of false-
positives observed with this assay. A subsequent section of this
report presents some possible reasons for false-positive events and
recommends further exploration of the root cause of systematic
false-positive events. Further development of this approach, under-
standing reasons for false-positives, and establishing metrics for
justiﬁcation to subtract a background of false-positives will emerge
from the community of dPCR practitioners.
4.1.2. EGFR T790M – veriﬁcation of linearity and sensitivity
A  mutation titration series was  evaluated in quadruplicate, and
the data are displayed in Fig. 8. The expected mutant to wild-type
ratio (solid red line) and 95% conﬁdence interval (dotted red lines)
are plotted along with the measured data. The data is congruent
with the expected concentration at the high values; it deviates
from the expected value at low mutant concentrations due to the
contribution of false-positive counts. Notice that the last titration
sample (R = 0.00065%) is a mutant concentration with an expected
value that is below the LoB. Indeed, none of the four replicates
at this concentration are signiﬁcantly different from the negative
controls.
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Fig. 8. EGFR T790M mutant titration series with four replicates of each concentra-
tion.
Table 8
Droplet event and molecule counts from 71 EGFR L858R wild-type samples.
Average Standard deviation Total
Total droplets
processed (N)
8,405,878  622,029 596,817,340
Mutant only droplets 0.06 0.23 4
Mutant molecules
(false  positives)
0.06  0.26 4.4
Wild-type only 861,260  82,956 61,149,444
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Fig. 9. LoD performance model for EGFR L858R. Blue points represent the empirical
data collected from 71 negative samples pooled to different levels. The red curve is an
extrapolation of the data to represent evaluation of more DNA. The green dashed line
is the LoD if the amount of DNA available for analysis is unlimited. (For interpretation
of  the references to color in this ﬁgure legend, the reader is referred to the web
version  of this article.)droplets
Wild-type molecules 908,851 89,513 64,528,410
.2. EGFR L858R assay characterization
.2.1. EGFR L858R limit of detection
Following the same analysis described in the previous sections,
ata from 71 wild-type samples and a mutant titration series was
rocessed to assess the sensitivity of the EGFR L858R assay. Table 8
ummarizes the data collected from wild-type samples (data for
ach individual sample are reported in Appendix Table A4).
Even  though there are very few false-positives detected by this
ssay, the LoD is modulated by the conservative ˇ-error of 5%.
or example, as displayed in Table 6, if an assay yields zero false-
ositives (FP = 0), at least three true mutants must be present to
imit the probability of making a false negative call to be below 5%.
imilarly, a single false-positive (FP = 1) among 1 million wild-
ype alleles dictates that a minimum of 9 true mutants must be
resent to maintain  ˛ and  ˇ errors of 5% or better, and the resulting
oD of this hypothetical example is 1 in 111,000.
Fig. 9 presents the assay LoD relative to the amount of DNA that
s evaluated. The blue data points display the demonstrated LoD
hat is achieved for a single sample (1 in 180,000), a sample with
nough DNA to be processed with eight assay reactions (1 in 1 mil-
ion), or by dividing a very large amount of DNA (230 g) into 71
ndividual samples for analysis, then recombination of data (1 in 4
illion) (see Appendix Table A8 for associated calculations). Similar
o the T790M assay, more DNA yields higher detection sensitivity.
n contrast to the T790M assay, the false-positive rate is extremely
ow, so the LoD is almost exclusively limited by the amount of DNA
rocessed and the LoD does not plateau until 1 in 14 million if one
ere to process hundreds of billions of wild-type molecules..2.2.  EGFR L858R – veriﬁcation of linearity and sensitivity
A  mutant titration series was evaluated in quadruplicate and the
ata are displayed in Fig. 10. Unlike the EGFR T790M assay, the dataFig. 10. EGFR L858R mutant titration series with four replicates of each concentra-
tion.
is linear throughout the whole titration range. Notice that the last
titration sample (R = 0.00053%) has a mutant concentration above
the LoB but below the LoD. For this experiment, all four replicates
are signiﬁcantly different than the negative controls, but if this sam-
ple were to be processed numerous times, it is anticipated from
the negative control data that more than 5% of the measurements
would fall below the LoB, leading to false-negative calls. This ambi-
guity, which arises from measuring a single or small number of
replicates, demonstrates the importance of calculating and under-
standing the LoB and LoD parameters, even for extremely sensitive
assays.
4.3. Comparing and contrasting EGFR assay performance
The results reveal a signiﬁcantly greater sensitivity associated
with the EGFR L858R assay in contrast to the EGFR T790M assay.
Many factors possibly contribute to the performance of an assay.
For example, the complexity of the sequence composition within
the targeted region, the primer and probe oligonucleotide design
and quality of synthesis, reagent quality, polymerase efﬁciency
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nd ﬁdelity, and sample preparation might inﬂuence the measured
ssay sensitivity.
Many commercially-available quantitative PCR (qPCR) assays
ail to enable highly sensitive mutation detection of EGFR T790M
ue to a number of compounding factors that reduce the speciﬁcity
f primers and probes leading to a relatively high level of signal
ackground (i.e., a high Cq). It is difﬁcult to design sensitive assays
or the EGFR T790M (c.2369C>T) point mutation. This region of
GFR (chr7:55259486-55259563) is relatively rich in guanine and
ytosine and exhibits sequence homology (∼83%) with the proto-
ncogene receptor tyrosine-protein kinase erbB-2 (HER2/neu). In
ddition to the high sequence similarities with HER2, this region of
GFR T790M contains a repetitive sequence element adjacent to the
utation, which creates a challenge to design robust probes with
igh speciﬁcity. Further adding to this challenge, there is a single
ucleotide polymorphism located eight nucleotides upstream from
he mutation, which limits primer design options. Some or all of the
hallenges associated with qPCR assay design might be reﬂected in
he lower sensitivity of the EGFR T790M dPCR assay.
Another hypothesis for the source of false-positives is that
utant DNA fragments are generated during the PCR reaction from
ild-type DNA fragments as a result of polymerase error. In princi-
le, one of the advantages of single-molecule partitioning with the
ainDropTM dPCR System is that the sensitivity of mutation detec-
ion is better than the polymerase error rate [9]. Polymerase errors
ypically occur as purine/purine (A ↔ G) or pyrimidine–pyrimidine
C ↔ T) transitions. Pyrimidine–purine transversions (A/G ↔ C/T)
re less common [19]. If a polymerase error occurs at or near the
ucleotide of interest, and results in an ampliﬁable fragment that
ybridizes with the mutant probe, then, due to the presence of the
nitial two complementary strands of wild type target, the resulting
roplet will produce ﬂuorescence signal from both wild-type and
utant probes. The level of polymerase error resulting in droplet
vents counted in the “dual” cluster can be determined by compar-
ng the actual count of events in the dual cluster to the expected
ount based on the Poisson loading calculations. Evidence of poly-
erase error with speciﬁc sequence targets has been observed,
hich supports this hypothesis. However, for the EGFR T790M
ssay, the false-positive background arises from droplet events
hat are characterized as mutant-only (“Mut” cluster). To satisfy
he hypothesis of polymerase error, another process or reaction
ust eliminate the ampliﬁcation and/or generation of ﬂuorescence
ignal from the original two wild-type template strands, and this
actor is not yet explained.
.4.  Additional cancer-based assays
Following the same methodologies presented herein, each of the
dditional sixteen assays was evaluated. Data from these assays
re presented in Appendix Table A2. As with EGFR T790M, some
ssays present an apparent level of low-level positives in the pre-
umably wild-type controls. As with EGFR T790M, it is difﬁcult to
ssign the source of these positives that reside within the mutant
ontrol gates. There are a couple assays that exhibit very few false-
ositives, as observed with EGFR L858R; namely PIK3CA H1047R
nd KRAS G12C. For these assays, data indicate that the sensitiv-
ty of the assays is largely dependent upon the amount of DNA
hat is evaluated. For both PIK3CA H1047R and KRAS G12C, fewer
olecules of wild-type DNA were evaluated than those evaluated
n the EGFR L858R assay. Similar to EGFR T790M, however, sev-
ral assays demonstrated assay LoDs of around 1 mutant in 20,000
ild-type molecules, as they too exhibited false positives in the
utant clusters gates. This screening of an additional sixteen assays
mphasizes the importance of evaluating assays with controls prior
o initiating a full analysis of critical samples. and Quantiﬁcation 1 (2014) 8–22 17
As  discussed in the section above, polymerase errors are more
likely to present as transitions than transversions. Within these six-
teen assays (as well as the EGFR assays), less sensitive LoDs were
observed for those assays whose targets are transitions. Out of 17
assays tested herein, all eight assays with G/C >A/T mutations have
much lower LoDs than the other mutations assed. Though further
evaluation is warranted, it is likely that the false positive rate and
assay LoD are inﬂuenced by polymerase errors.
5. Conclusion
The performance of the EGFR assays in the RainDrop® Digital
PCR System demonstrates unprecedented sensitivity. The data pre-
sented demonstrate that the sensitivity of digital PCR assays is often
limited by the amount of DNA that is evaluated, and it is possible
to achieve sensitivity for detection of mutant alleles that is orders
of magnitude better than most alternative technologies.
A LoD for the EGFR T790M assay has been determined at 1 in
13,000 for a single sample at maximum loading, and up to 1 in
22,000 with unlimited DNA (or 1 in 34,000 for a single sample
if false-positives are qualiﬁed to be a systematic offset and sub-
tracted). For this assay, the primer and probe design challenges or
polymerase errors are factors that impact the ultimate sensitivity
but single molecule dPCR overcomes many sensitivity limitations
that arise from environments containing many target molecules.
Finally,  for the EGFR L858R assay, we  have empirically demon-
strated sensitivity of 1 in 180,000 for a single sample. Moreover, by
extrapolation, we  have determined that the EGFR L858R assay can
reach a LoD that far surpasses empirical data (i.e., 1 in 14 million),
and, in practice, the sensitivity is limited only by the amount of
sample DNA that is processed.
This report provides guidance on the analysis of digital PCR
data and it reveals some topics worthy of deeper exploration.
Firm understanding of the molecular biology and technology con-
tributions to false-positive droplet events is crucial for improved
sensitivity. Also, validation of objective automated gating of droplet
event clusters is likely necessary for dPCR practitioners to take
advantage of the full potential sensitivity of the technology for rou-
tine applications. Finally, availability of DNA reference materials
will enable validation within and across platforms.
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Appendix A.
A.1.  Alternative Poisson correction approach for duplex assays
As  discussed in the main text, four distinct clusters of droplet
events could be gated and counted in a typical duplex assay (i.e.,
NWT, NMut, NDual, and NNeg), and their relationships to m and w
are described in Eqs. (5)–(8). Mathematically, there are more than
one combination of (5)–(8) that could lead to the solution for m
and w. Although the expressions are more complex, Eqs. (9)–(10)
are recommended for most duplex assay applications because the
accuracy of the cluster counts are less susceptible to assay or system
noise, which is often located near and between the PCR-negative
cluster and the dual-occupancy cluster.
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A simpler solution comes from employing the PCR-negative
luster (NNeg) in Eq. (7), by dividing Eq. (5) or (6) by (7), and m
nd w follow:
w = ln
(
1 + NWT
NNeg
)
m = ln
(
1 + NMut
NNeg
)
Another alternative solution from using the combination of Eqs.
5)–(7) is by adding (5) and (7) or (6) and (7), to yield w and m as
ollows:
w = ln
(
N
NNeg + NMut
)m = ln
(
N
NNeg + NWT
)
able A1
ixteen cancer assay sequences and probe chemistries evaluated in addition to EGFR L858
Target Oligonucleotide Sequence 
Epidermal growth factor receptor
(EGFR) p.E746 A750del, c.2235del15
WT  PROBE VIC-ATTAAGAGAAGC
MUTANT PROBE 6FAM-TCGCTATCAAA
FORWARD PRIMER 5′-CTGGATCCCAGAA
REVERSE PRIMER 5′-CCACACAGCAAAG
Phosphoinositide-3-kinase, catalytic,
alpha polypeptide (PIK3CA)
p.H1047R,  c.3140A>G
WT PROBE /5TET/C+CATG+A+T+
MUTANT  PROBE /56-FAM/C+CATG+A+
FORWARD  PRIMER 5′-GAGCAAGAGGCTT
REVERSE PRIMER 5′-ATGCTGTTTAATTG
Phosphoinositide-3-kinase, catalytic,
alpha polypeptide (PIK3CA)
p.E545K,  c.1633G>A
WT PROBE /5TET/CCT +GC+T +C+
MUTANT  PROBE /56-FAM/TC+C TGC +
FORWARD  PRIMER 5′-GACAAAGAACAGC
REVERSE PRIMER 5′-GCACTTACCTGTGA
Murine sarcoma viral oncogene
homolog  B1 (BRAF)
p.V600E,  c.1799T>A
WT PROBE /5TET/TCGAGAT+TTC
MUTANT  PROBE /56-FAM/TCGAGAT+T
FORWARD  PRIMER 5′-ACCTCAGATATATT
REVERSE PRIMER 5′-CCAGACAACTGTTC
Anaplastic lymphoma receptor
tyrosine kinase (ALK)
p.R1275Q,  c.3824G>A
WT PROBE VIC-TGGCCCGAGACA
MUTANT PROBE 6FAM-TGGCCCAAGA
FORWARD PRIMER 5′-GGAAGAGTGGCCA
REVERSE PRIMER 5′-TGAGGCAGTCTTTA
Kirsten rat sarcoma viral oncogene
homolog (KRAS)
p.G12D,  c.35G>A
WT PROBE VIC-TTGGAGCTGGTG
MUTANT PROBE 6FAM-TTGGAGCTGA
FORWARD PRIMER 5′-CTGAAAATGACTG
REVERSE PRIMER 5′-TAGCTGTATCGTCA
Kirsten rat sarcoma viral oncogene
homolog (KRAS)
p.G12C,  c.34G>T
WT PROBE VIC-TTGGAGCTGGTG
MUTANT PROBE 6FAM-TTGGAGCTTG
FORWARD PRIMER 5′-CTGAAAATGACTG
REVERSE PRIMER 5′-TAGCTGTATCGTCA
Kirsten rat sarcoma viral oncogene
homolog (KRAS)
p.G12V,  c.35G>T
WT PROBE VIC-TTGGAGCTGGTG
MUTANT PROBE 6FAM-TTGGAGCTGT
FORWARD PRIMER 5′-CTGAAAATGACTG
REVERSE PRIMER 5′-TAGCTGTATCGTCA
Kirsten rat sarcoma viral oncogene
homolog (KRAS)
p.G12S,  c.34G>A
WT PROBE VIC-TTGGAGCTGGTG
MUTANT PROBE 6FAM-TTGGAGCTAG
FORWARD PRIMER 5′-CTGAAAATGACTG
REVERSE PRIMER 5′-TAGCTGTATCGTCA
Kirsten rat sarcoma viral oncogene
homolog (KRAS)
p.G12A,  c.35G>C
WT PROBE VIC-TTGGAGCTGGTG
MUTANT PROBE 6FAM-TTGGAGCTGC
FORWARD PRIMER 5′-CTGAAAATGACTG
REVERSE PRIMER 5′-TAGCTGTATCGTCA
Kirsten rat sarcoma viral oncogene
homolog (KRAS)
p.G12R,  c.34G>C
WT PROBE VIC-TTGGAGCTGGTG
MUTANT PROBE 6FAM-TTGGAGCTCG
FORWARD PRIMER 5′-CTGAAAATGACTG
REVERSE PRIMER 5′-TAGCTGTATCGTCAn and Quantiﬁcation 1 (2014) 8–22
Finally, if no cluster counts are known to be susceptible to
poor resolution and/or count accuracy, then one might wish to
take all counts into consideration. This approach would yield an
over-determined system of equations that would be solved by a
regression method.
The  best approach is to apply the various combinations for
analysis of known samples to determine which approach yields
the most accurate ﬁnal result. This statement and the discussion
throughout this report highlight the importance of development,
distribution, and maintenance of DNA reference materials to
enable digital PCR developers and practitioners to recommend
appropriate measurement and analysis methods, deﬁne perfor-
mance speciﬁcations accurately, and validate data – especially
clinical data – from multiple instruments and technology plat-
forms.See Tables A1–A8.
R and T790M.
Probe type Vendor
AACATCTCCGA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
ACATCTCCGA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
GGTGAGA-3′
CAGAAAC-3′
GT/ZEN/G+CAT/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
C+GT/ZEN/GCAT/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
TGGAGTA-3′
TGTGGAAGA-3′
AG/ZEN/TG+AT/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
T+T+A/ZEN/+GT+G/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
TCAAAGCA-3′
CTCCAT-3′
+ACT+GTAGCT/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
TC+TCT+GTAGCT/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
TCTTCATG-3′
AAAC-3′
TC-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
CATC-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
AGATTGGA-3′
CTCACCTGTA-3′
GCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
TGGCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
AATATAAACTTGTGG-3′
AGGCACTC-3′
GCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
TGGCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
AATATAAACTTGTGG-3′
AGGCACTC-3′
GCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
TGGCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
AATATAAACTTGTGG-3′
AGGCACTC-3′
GCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
TGGCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
AATATAAACTTGTGG-3′
AGGCACTC-3′
GCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
TGGCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
AATATAAACTTGTGG-3′
AGGCACTC-3′
GCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
TGGCGTA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
AATATAAACTTGTGG-3′
AGGCACTC-3′
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Table  A1 (Continued)
Target Oligonucleotide Sequence Probe type Vendor
Kirsten rat sarcoma viral oncogene
homolog (KRAS)
p.G13D,  c.38G>A
WT  PROBE VIC-CTGGTGGCGTAGGC-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
MUTANT  PROBE 6FAM-CTGGTGACGTAGGC-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
FORWARD  PRIMER 5′-CTGAAAATGACTGAATATAAACTTGTGG-3′
REVERSE PRIMER 5′-TAGCTGTATCGTCAAGGCACTC-3′
Human Epidermal Growth Factor
Receptor 2 (HER2)
p.L755S,  c.2264T>C
WT  PROBE 6FAM-TCCCTCAACACTTTG-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
MUTANT  PROBE VIC-TCCCTCGACACTTTG-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
FORWARD  PRIMER 5′-CCTGATGGGGAGAATGTGAA-3′
REVERSE PRIMER 5′-GTGGAGGGGCTTACGTCTAA-3′
Guanine Nucleotide Binding Protein (G
Protein), Alpha Stimulating Activity
Polypeptide (GNAS)
p.R201C,  c.601C>T
WT  PROBE /5TET/tcgc+Tgc+Cgt+Gtcc/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
MUTANT PROBE /56-FAM/tcgc+Tgc+Tgt+Gtcc/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
FORWARD PRIMER 5′-ACCTCAGATATATTTCTTCATG-3′
REVERSE PRIMER 5′-CCAGACAACTGTTCAAAC-3′
Guanine Nucleotide Binding Protein (G
Protein), Alpha Stimulating Activity
Polypeptide (GNAS)
p.R201H,  c.602G>A
WT  PROBE /5TET/tcgc+Tgc+Cgt+Gtcc/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
MUTANT PROBE /56-FAM/cgct+Gcc+Atg+Tcct/3IABkFQ/ LNA-ZEN Integrated DNA Technologies
FORWARD PRIMER 5′-ACCTCAGATATATTTCTTCATG-3′
REVERSE PRIMER 5′-CCAGACAACTGTTCAAAC-3′
Tumor Suppressor Protein P53 (TP53)
p.R273H, c.818G>A
WT  PROBE VIC-ACAAACACGCACCTCA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
MUTANT  PROBE 6FAM-ACAAACATGCACCTCA-MGBNFQ TAQMAN MGB  LIFE TECHNOLOGIES
FORWARD  PRIMER 5′-TGGTAATCTACTGGGACGGAACAGC-3′
REVERSE PRIMER 5′-GGAGATTCTCTTCCTCTGTG-3′
Table A2
Sixteen cancer-based assays evaluated, in addition to the EGFR L858R and T790M assays, following the approach described herein. The best empirical LoD was calculated for
using  the number of wild-type DNA molecules evaluated.
Gene Protein variant Nucleotide variant Best empirical LoD # WT  DNA molecules evaluated Estimated LoD with unlimited DNA
EGFR p.E746 A750del c.2235del15 1:648,000 1.7E+07 1:1.5 million (0.00006%)
BRAF  p.V600E c.1799T>A 1:340,000 1.6E+07 1:615,000 (0.00016%)
PIK3CA  p.H1047R c.3140A>G 1:1.3 million 2.0E+07 1:5 million (0.00009%)
PIK3CA  p.E545K c.1633G>A 1:66,000 2.1E+07 1:80,000 (0.0012%)
ALK  p.R1275Q c.3824G>A 1:26,000 2.1E+07 1:30,000 (0.003%)
KRAS  p.G12C c.34G>T 1:940,000 2.5E+07 1:2.2 million (0.00004%)
KRAS  p.G12D c.35G>A 1:45,000 3.5E+07 1:46,500 (0.002%)
KRAS  p.G12S c.34G>A 1:59,000 2.3E+07 1:70,000 (0.0014%)
KRAS  p.G12V c.35G>T 1:425,000 2.4E+07 1:720,000 (0.00014%)
KRAS  p.G12A c.35G>C 1:290,000 2.2E+07 1:455,000 (0.0002%)
KRAS  p.G12R c.34G>C 1:290,000 2.2E+07 1:450,000 (0.0002%)
KRAS  p.G13D c.38G>A 1:19,000 2.0E+07 1:21,000 (0.005%)
HER2 p.L755S  c.2264C>T 1:185,000 2.4E+07 1:255,000 (0.0004%)
GNAS  p.R201C c.601C>T 1:19,000 2.0E+07 1:21,000 (0.0048%)
GNAS  p.R201H c.602G>A 1:17,000 2.0E+07 1:18,000 (0.0055%)
TP53  p.R273H c.818G>A 1:19,600 2.0E+07 1:22,000 (0.0045%)
Table A3
Poisson correction for 58 negative samples for EGFR T790M assay. N is the total measured droplet count, NWT is the count of wild-type only drops; NMut is the count of mutant
only drops; w is the measured wild-type loading, m the mutant loading, calculated following Eq. (9)–(10); R is the ratio of mutant to wild type in the sample; RFP is the
average R of the 58 negative controls, RFP = 4.5e−5.
Sample Droplet count Loading R Target count
N NMut NWT m w #WT  #Mut
1 9,292,320 39 857,246 4.6E−06 9.7E−02 0.0048% 899,406 43
2  8,751,560 38 792,909 4.8E−06 9.5E−02 0.0050% 831,161 42
3  9,661,960 45 870,560 5.1E−06 9.4E−02 0.0054% 912,312 49
4  8,520,880 24 762,983 3.1E−06 9.4E−02 0.0033% 799,332 26
5  8,272,480 32 733,229 4.2E−06 9.3E−02 0.0046% 767,785 35
6  8,697,580 26 762,866 3.3E−06 9.2E−02 0.0036% 798,419 28
7  8,765,590 37 763,351 4.6E−06 9.1E−02 0.0051% 798,658 41
8  7,788,450 28 683,666 3.9E−06 9.2E−02 0.0043% 715,555 31
9  9,399,530 43 862,734 5.0E−06 9.6E−02 0.0052% 904,934 47
10  9,857,770 32 886,833 3.6E−06 9.4E−02 0.0038% 929,294 35
11  8,913,880 28 809,859 3.5E−06 9.5E−02 0.0036% 849,043 31
12  7,878,070 35 688,037 4.9E−06 9.1E−02 0.0053% 719,958 38
13  8,629,560 22 764,766 2.8E−06 9.3E−02 0.0030% 800,801 24
14  8,733,070 33 778,805 4.1E−06 9.3E−02 0.0044% 815,748 36
15  8,223,940 36 750,831 4.8E−06 9.6E−02 0.0050% 787,350 40
16  7,189,280 28 683,011 4.3E−06 1.0E−01 0.0043% 717,672 31
17  8,628,230 32 778,454 4.1E−06 9.5E−02 0.0043% 815,841 35
18  8,682,560 29 806,395 3.7E−06 9.7E−02 0.0038% 846,338 32
19  9,258,960 43 808,417 5.1E−06 9.1E−02 0.0056% 845,913 47
20  9,074,190 44 793,753 5.3E−06 9.2E−02 0.0058% 830,641 48
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Table  A3 (Continued)
Sample Droplet count Loading R Target count
N NMut NWT m w #WT  #Mut
21 8,833,630 23 778,397 2.9E−06 9.2E−02 0.0031% 814,853 25
22  8,650,790 32 775,301 4.1E−06 9.4E−02 0.0043% 812,273 35
23  9,359,870 34 867,254 4.0E−06 9.7E−02 0.0041% 910,104 37
24  8,749,980 49 807,034 6.2E−06 9.7E−02  0.0064% 846,716 54
25  9,924,810 36 904,048 4.0E−06 9.6E−02 0.0042% 947,911 40
26  9,273,750 44 852,782 5.2E−06 9.6E−02 0.0054% 894,579 48
27  9,238,320 33 828,852 3.9E−06 9.4E−02 0.0042% 868,423 36
28  10,142,200 40 891,111 4.3E−06 9.2E−02 0.0047% 932,718 44
29  9,452,310 49 831,402 5.7E−06 9.2E−02 0.0062% 870,267 54
30  10,307,200 46 901,286 4.9E−06 9.2E−02 0.0053% 943,155 50
31  8,824,910 45 836,557 5.6E−06 1.0E−01  0.0057% 878,912 50
32  10,015,800 38 935,156 4.2E−06 9.8E−02 0.0043% 981,740 42
33  9,594,880 38 881,745 4.4E−06 9.6E−02 0.0045% 924,931 42
34  9,626,790 42 906,768 4.8E−06 9.9E−02 0.0049% 952,365 46
35  8,497,390 40 767,334 5.2E−06 9.5E−02 0.0055% 804,222 44
36  9,338,540 46 834,294 5.4E−06 9.4E−02 0.0058% 873,946 51
37  8,948,330 27 802,349 3.3E−06 9.4E−02 0.0035% 840,629 30
38  9,194,420 29 824,632 3.5E−06 9.4E−02 0.0037% 863,986 32
39  9,665,900 33 909,850 3.8E−06 9.9E−02 0.0038% 955,568 36
40  8,631,750 41 813,778 5.2E−06 9.9E−02 0.0053% 854,739 45
41  8,451,160 31 784,877 4.0E−06 9.7E−02 0.0041% 823,754 34
42  10,825,000 41 1,020,960 4.2E−06 9.9E−02 0.0042% 1,072,370 45
43  10,332,800 45 950,164 4.8E−06 9.6E−02 0.0050% 996,733 50
44  9,414,420 29 857,467 3.4E−06 9.5E−02 0.0035% 899,065 32
45  9,909,550 32 900,658 3.6E−06 9.5E−02 0.0037% 944,253 35
46  9,023,920 28 832,170 3.4E−06 9.7E−02 0.0035% 873,079 31
47  9,110,150 36 823,009 4.3E−06 9.5E−02 0.0046% 862,591 40
48  8,620,500 25 784,679 3.2E−06 9.5E−02 0.0033% 822,721 28
49  8,238,160 31 749,670 4.1E−06 9.5E−02 0.0043% 786,005 34
50  8,225,370 29 734,577 3.9E−06 9.4E−02 0.0041% 769,475 32
51  8,585,660 29 772,546 3.7E−06 9.4E−02 0.0039% 809,543 32
52  9,058,930 43 859,634 5.2E−06 1.0E−01  0.0053% 903,205 48
53  10,044,100 30 957,633 3.3E−06 1.0E−01 0.0033% 1,006,415 33
54  9,342,810 40 868,684 4.7E−06 9.8E−02 0.0048% 911,765 44
55  8,217,480 43 757,698 5.8E−06 9.7E−02 0.0060% 794,942 47
56  9,048,170 44 823,129 5.3E−06 9.5E−02 0.0056% 863,012 48
57  8,718,730 29 798,698 3.7E−06 9.6E−02 0.0038% 837,684 32
58  9,225,920 35 829,971 4.2E−06 9.4E−02 0.0044% 869,709 38
Table A4
Poisson correction for 71 negative samples for EGFR L858R assay. RFP = 7.1e−8.
Sample Droplet count Loading R Target count
N NMut NWT m w #WT  #Mut
1 7,221,390 0 680,170 0.0E+00 9.9E−02 0.0E+00 714,367 0
2  8,099,920 0 774,847 0.0E+00 1.0E−01 0.0E+00 814,456 0
3  8,498,880 0 815,968 0.0E+00 1.0E−01 0.0E+00 857,841 0
4  8,436,800 0 830,430 0.0E+00 1.0E−01 0.0E+00 874,196 0
5  7,943,180 0 729,851 0.0E+00 9.6E−02 0.0E+00 765,589 0
6  7,454,740 0 685,925 0.0E+00 9.7E−02 0.0E+00 719,562 0
7  9,147,660 1 809,388 1.2E−07 9.3E−02 1.3E−06 847,459 1.1
8  9,288,860 0 834,079 0.0E+00 9.4E−02 0.0E+00 873,931 0
9  8,437,430 0 828,280 0.0E+00 1.0E−01 0.0E+00 871,808 0
10  6,545,580 0 636,378 0.0E+00 1.0E−01 0.0E+00 669,477 0
11  8,117,250 0 810,659 0.0E+00 1.1E−01 0.0E+00 854,053 0
12  8,710,990 0 854,799 0.0E+00 1.0E−01 0.0E+00 899,702 0
13  7,509,460 0 719,880 0.0E+00 1.0E−01 0.0E+00 756,762 0
14  8,328,420 0 798,532 0.0E+00 1.0E−01 0.0E+00 839,451 0
15  8,602,610 0 781,659 0.0E+00 9.5E−02 0.0E+00 819,480 0
16  9,974,820 0 894,498 0.0E+00 9.4E−02 0.0E+00 937,177 0
17  8,236,180 0 787,741 0.0E+00 1.0E−01 0.0E+00 828,001 0
18  7,667,560 0 748,526 0.0E+00 1.0E−01 0.0E+00 787,629 0
19  8,703,550 0 854,263 0.0E+00 1.0E−01 0.0E+00 899,149 0
20  8,519,800 0 836,964 0.0E+00 1.0E−01 0.0E+00 880,982 0
21  7,512,580 0 695,574 0.0E+00 9.7E−02 0.0E+00 729,912 0
22  8,167,940 0 772,241 0.0E+00 9.9E−02 0.0E+00 811,224 0
23  8,137,700 1 739,786 1.4E−07 9.5E−02 1.4E−06 775,600 1.1
24  6,794,800 0 766,088 0.0E+00 1.2E−01 0.0E+00 812,823 0
25  8,053,820 0 856,069 0.0E+00 1.1E−01 0.0E+00 905,071 0
26  8,350,220 0 943,007 0.0E+00 1.2E−01 0.0E+00 1,000,637 0
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Table  A4 (Continued)
Sample Droplet count Loading R Target count
N NMut NWT m w #WT  #Mut
27 8,712,660 0 969,456 0.0E+00 1.2E−01 0.0E+00 1,027,759 0
28  6,968,880 0 739,934 0.0E+00 1.1E−01 0.0E+00 782,239 0
29  8,043,370 0 834,480 0.0E+00 1.1E−01 0.0E+00 881,016 0
30  8,311,230 0 878,618 0.0E+00 1.1E−01 0.0E+00 928,616 0
31  9,628,460 0 999,325 0.0E+00 1.1E−01 0.0E+00 1,055,077 0
32  8,712,960 0 930,813 0.0E+00 1.1E−01 0.0E+00 984,384 0
33  9,316,300 0 930,892 0.0E+00 1.1E−01 0.0E+00 980,750 0
34  8,620,290 0 928,510 0.0E+00 1.1E−01 0.0E+00 982,424 0
35  8,928,080 0 963,637 0.0E+00 1.1E−01 0.0E+00 1,019,715 0
36  8,603,120 0 890,080 0.0E+00 1.1E−01 0.0E+00 939,568 0
37  8,377,540 0 875,373 0.0E+00 1.1E−01 0.0E+00 924,565 0
38  7,993,710 0 834,634 0.0E+00 1.1E−01 0.0E+00 881,499 0
39  9,129,150 0 975,721 0.0E+00 1.1E−01 0.0E+00 1,031,904 0
40  8,453,960 0 897,837 0.0E+00 1.1E−01 0.0E+00 949,183 0
41  9,034,090 0 908,822 0.0E+00 1.1E−01 0.0E+00 957,853 0
42  8,289,420 0 896,566 0.0E+00 1.1E−01 0.0E+00 948,858 0
43  8,441,650 0 921,643 0.0E+00 1.2E−01 0.0E+00 975,945 0
44  7,925,780 0 814,854 0.0E+00 1.1E−01 0.0E+00 859,854 0
45  8,879,910 0 919,898 0.0E+00 1.1E−01 0.0E+00 971,115 0
46  7,887,010 0 819,608 0.0E+00 1.1E−01 0.0E+00 865,396 0
47  9,008,630 0 942,661 0.0E+00 1.1E−01 0.0E+00 995,716 0
48  7,895,160 0 852,831 0.0E+00 1.1E−01 0.0E+00 902,503 0
49  8,621,540 0 875,833 0.0E+00 1.1E−01 0.0E+00 923,582 0
50  8,792,080 0 937,430 0.0E+00 1.1E−01 0.0E+00 991,268 0
51  8,656,130 1 941,022 1.3E−07 1.2E−01 1.1E−06 996,210 1.1
52  8,269,540 0 852,238 0.0E+00 1.1E−01 0.0E+00 899,424 0
53  8,578,770 0 876,470 0.0E+00 1.1E−01 0.0E+00 924,547 0
54  8,464,580 0 857,687 0.0E+00 1.1E−01 0.0E+00 904,318 0
55  8,835,740 0 911,090 0.0E+00 1.1E−01 0.0E+00 961,564 0
56  8,568,860 0 936,126 0.0E+00 1.2E−01 0.0E+00 991,319 0
57  8,713,740 0 890,786 0.0E+00 1.1E−01 0.0E+00 939,680 0
58  8,449,810 0 921,728 0.0E+00 1.2E−01 0.0E+00 975,984 0
59  8,726,290 0 941,135 0.0E+00 1.1E−01 0.0E+00 995,858 0
60  7,648,540 0 812,500 0.0E+00 1.1E−01 0.0E+00 858,978 0
61  8,378,460 1 881,857 1.3E−07 1.1E−01 1.2E−06 931,803 1.1
62  7,780,120 0 823,354 0.0E+00 1.1E−01 0.0E+00 870,261 0
63  8,732,820 0 911,819 0.0E+00 1.1E−01 0.0E+00 963,019 0
64  8,778,120 0 977,732 0.0E+00 1.2E−01 0.0E+00 1,036,598 0
65  8,157,080 0 863,753 0.0E+00 1.1E−01 0.0E+00 912,993 0
66  8,359,880 0 928,319 0.0E+00 1.2E−01 0.0E+00 984,026 0
67  9,002,200 0 999,617 0.0E+00 1.2E−01 0.0E+00 1,059,601 0
68  8,851,780 0 941,824 0.0E+00 1.1E−01 0.0E+00 995,793 0
69  9,687,240 0 977,081 0.0E+00 1.1E−01 0.0E+00 1,029,943 0
70  8,771,750 0 954,042 0.0E+00 1.2E−01 0.0E+00 1,010,022 0
71  8,368,770 0 924,206 0.0E+00 1.2E−01 0.0E+00 979,337 0
Table A5
Poisson correction for 16 mutant titration samples for EGFR T790M assay. [WT] is the measured concentration of wild type DNA and [Mut] the concentration of mutant DNA
in  the sample. #Mut target is the measured count of mutant DNA molecules. FP = RFP*N*w; p-value is calculated following Eq. (14). RFP = 4.5e−5.
Sample Droplet count Loading Mut/WT [Target] (copies/l) p-Value calculation
N #WT  #Mut w m R [WT] [Mut] #Mut target FP p-Value
1 9,142,560 814,578 41 9.3E−02 4.9E−06 0.0053% 1.9E+04 9.8E−01 45 39 1.7E−01
2  9,838,690 903,463 44 9.6E−02 4.9E−06 0.0051% 1.9E+04 9.8E−01 48 43 2.4E−01
3  9,573,960 870,985 44 9.5E−02 5.1E−06 0.0053% 1.9E+04 1.0E+00 48 41 1.7E−01
4  8,994,840 789,122 44 9.2E−02 5.4E−06 0.0058% 1.8E+04 1.1E+00 48 37 5.4E−02
5  9,447,200 843,816 74 9.4E−02 8.6E−06 0.0092% 1.9E+04 1.7E+00 81 40 8.7E−09
6  9,121,840 810,395 80 9.3E−02 9.6E−06 0.010% 1.9E+04 1.9E+00 88 38 1.3E−11
7  9,583,900 839,461 82 9.2E−02 9.4E−06 0.010% 1.8E+04 1.9E+00 90 40 1.4E−11
8  9,861,590 897,266 108 9.5E−02 1.2E−05 0.013% 1.9E+04 2.4E+00 119 43 0.0E+00
9  8,282,410 745,192 470 9.4E−02 6.2E−05 0.066% 1.9E+04 1.2E+01 516 35 0.0E+00
10  9,669,580 845,055 524 9.1E−02 5.9E−05 0.065% 1.8E+04 1.2E+01 574 40 0.0E+00
11  9,470,450 863,718 549 9.6E−02 6.4E−05 0.067% 1.9E+04 1.3E+01 604 41 0.0E+00
12  10,087,300 917,273 566 9.5E−02 6.2E−05 0.065% 1.9E+04 1.2E+01 623 44 0.0E+00
13  9,257,860 826,623 5211 9.4E−02 6.2E−04 0.66% 1.9E+04 1.2E+02 5724 39 0.0E+00
14  9,830,510 871,282 5362 9.3E−02 6.0E−04 0.64% 1.9E+04 1.2E+02 5886 41 0.0E+00
15  9,690,850 867,214 5362 9.4E−02 6.1E−04 0.65% 1.9E+04 1.2E+02 5891 41 0.0E+00
16  10,503,100 920,328 5710 9.2E−02 6.0E−04 0.65% 1.8E+04 1.2E+02 6261 44 0.0E+00
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Table  A6
Poisson correction for 16 mutation titration samples for EGFR L858R. RFP = 7.1e−8.
Sample Droplet Count Loading Mut/WT [target] (copies/l) p-Value calculation
N #WT  #Mut w m R [WT] [Mut] #Mut target FP p-Value
1 8,368,910 884,438 2 1.1E−01 2.7E−07 2.4E−06 2.2E+04 5.3E−02 2.2 0.07 2.1E−03
2  8,402,990 836,013 5 1.0E−01 6.6E−07 6.3E−06 2.1E+04 1.3E−01 5.6 0.06 7.3E−09
3  8,680,540 918,607 3 1.1E−01 3.9E−07  3.5E−06 2.2E+04 7.7E−02 3.4 0.07 5.1E−05
4  8,916,470 906,360 2 1.1E−01 2.5E−07 2.3E−06 2.1E+04 5.0E−02 2.2 0.07 2.2E−03
5  8,349,320 910,776 46 1.2E−01 6.2E−06 5.4E−05 2.3E+04 1.2E+00 52 0.07 0.0E+00
6  8,428,520 890,651 49 1.1E−01 6.5E−06 5.8E−05 2.2E+04 1.3E+00 55 0.07 0.0E+00
7  8,641,460 928,568 45 1.1E−01 5.8E−06 5.1E−05 2.3E+04 1.2E+00 50 0.07 0.0E+00
8  8,393,990 923,295 41 1.2E−01 5.5E−06 4.7E−05 2.3E+04 1.1E+00 46 0.07 0.0E+00
9  8,213,490 851,897 460 1.1E−01 6.2E−05 5.7E−04  2.2E+04 1.2E+01 513 0.06 0.0E+00
10  8,832,850 916,347 495 1.1E−01 6.3E−05  5.7E−04 2.2E+04 1.3E+01 552 0.07 0.0E+00
11  8,079,670 848,026 483 1.1E−01 6.7E−05 6.0E−04 2.2E+04 1.3E+01 540 0.06 0.0E+00
12  8,715,960 903,618 440 1.1E−01 5.6E−05 5.1E−04 2.2E+04 1.1E+01 491 0.07 0.0E+00
13  7,638,330 797,689 3985 1.1E−01 5.8E−04 5.3E−03 2.2E+04 1.2E+02 4451 0.06 0.0E+00
14  8,604,530 886,040 4346 1.1E−01 5.6E−04 
15  8,386,260 851,848 4256 1.1E−01 5.7E−04 
16  7,999,900 844,015 4293 1.1E−01 6.0E−04 
Table A7
Calculation of LoB and LoD from EGFR T790M assay data. RFP is the average false
positive  ratios of negative control samples, #WT avg is the average of the wild-type
load  per sample, FP is the average of the false mutant counts. LoB and LoD are limit
of blank and lower limit of detection of mutant counts at #W avg load, R LoB and
R LoD are the limit of blank and lower limit of detection expressed in R.
RFP #WT avg FP LoB LoD R LoB R LoD
4.5E−05 8.6E+05 39 50.1 64.0 0.0058% 0.0074%
Table A8
Calculation of LoB and LoD for EGFR L858R.
#
R
[
[
[
[
[
[
[
[RFP WT avg FP LoB LoD R LoB R LoD
7.1E−08 9.1E+05 0.06 1.3 5.0 0.00014% 0.00054%
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